Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 117, Issue 6, Pages 1699-1707Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI30575
Keywords
-
Categories
Funding
- NHLBI NIH HHS [R37-HL41002, R37 HL041002] Funding Source: Medline
- NICHD NIH HHS [R01-HD28341, R01 HD028341] Funding Source: Medline
- NIMH NIH HHS [F32 MH065815, F32-MH065815] Funding Source: Medline
Ask authors/readers for more resources
Single gene mutations in beta integrins can account for functional defects of individual cells of the hematopoietic system. In humans, mutations in beta(2) integrin lead to leukocyte adhesion deficiency (LAD) syndrome and mutations in beta(3) integrin cause the bleeding disorder Glanzmarm thrombasthenia. However, multiple defects in blood cells involving various beta integrins (beta(1), beta(2), and beta(3)) occur simultaneously in patients with the recently described LAD type III (LAD-III). Here we show that the product of a single gene, Ca2+ and diacylglycerol-regulated guanine nucleotide exchange factor 1 (CaIDAG-GEFI), controlled the activation of all 3 integrins in the hematopoietic system. Neutrophils from CalDAG-GEFI(-/-) mice exhibited strong defects in Rap1 and beta(1) and beta(2) integrin activation while maintaining normal calcium flux, degranulation, and ROS generation. Neutrophils from CalDAG-GEFI deficient mice failed to adhere firmly to stimulated venules and to migrate into sites of inflammation. Furthermore, CaIDAG-GEFI regulated the activation of beta(1) and beta(3) integrins in platelets, and CaIDAG-GEFI deficiency caused complete inhibition of arterial thrombus formation in mice. Thus, mice engineered to lack
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available